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A promising direction in drug development is to exploit the ability of natural killer cells to kill
antibody-labeled target cells. Monoclonal antibodies and drugs designed to elicit this effect typically
bind cell-surface epitopes that are overexpressed on target cells but also present on other cells. Thus
it is important to understand adhesion of cells by antibodies and similar molecules. We present an
equilibrium model of such adhesion, incorporating heterogeneity in target cell epitope density and
epitope immobility. We compare with experiments on the adhesion of Jurkat T cells to bilayers
containing the relevant natural killer cell receptor, with adhesion mediated by the drug alefacept.
We show that a model in which all target cell epitopes are mobile and available is inconsistent with
the data, suggesting that more complex mechanisms are at work. We hypothesize that the immobile
epitope fraction may change with cell adhesion, and we find that such a model is more consistent
with the data. We also quantitatively describe the parameter space in which binding occurs. Our
results point toward mechanisms relating epitope immobility to cell adhesion and offer insight into
the activity of an important class of drugs.
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I. INTRODUCTION
When a pathogen elicits a humoral immune response,
antibodies are produced that bind to specific epitopes
on the surface of the pathogen. Once antibodies have
bound to the pathogen it is labeled as foreign, and vari-
ous processes can follow that lead to its elimination. One
such process, antibody-dependent cell-mediated cytotox-
icity (ADCC), involves natural killer (NK) cells binding
through their FcγRIIIa (CD16a) receptors to IgG anti-
bodies decorating the pathogen (reviewed in [1]). The
coupling of an NK cell to a target cell brings parts of the
surfaces of the two cells into proximity, within roughly
100 A˚. In the region of tight contact where antibodies
form bridges between the two cells, both the density of
epitopes on the target cell and the density of Fc receptors
on the NK cell are locally increased. When the density
of Fc receptors in the contact region on the NK cell is
sufficiently high, a cellular response is triggered, the end
point of which is the release of lytic granules containing
perforin and granzymes, whose combined effect results
in the killing of the target cell [2–4]. Depending on the
nature of the epitope and type of cell, the aggregation
of epitopes on the target cell may also trigger cellular
responses [5, 6].
Monoclonal antibodies and antibody-like fusion pro-
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teins have been developed to take advantage of ADCC.
These drugs target naturally occurring proteins that are
overexpressed on tumor cells and on populations of cells
that drive autoimmune responses [1, 7–10]. Unfortu-
nately the drug will also target a subset of healthy cells
because the target is a naturally occurring protein. An
obvious question, which we address in this paper, is what
properties of the drug, the cells that express the target
protein, and the NK cells determine the drug’s ability
to discriminate between pathogenic and healthy cells? A
second question that we consider, that is closely related
to the first, is what determines the range of drug concen-
trations over which the drug will couple target cells to
NK cells? These drugs, either in animal models or pa-
tients, must compete for Fc receptors on NK cells with
endogenous IgG [11]. We therefore also look at how back-
ground IgG influences the range of drug concentrations
over which adhesion occurs.
We previously presented an equilibrium model that de-
scribes the coupling via a monoclonal antibody (or an
appropriate fusion protein) of identical target cells to a
surface expressing mobile Fc receptors [12]. Here, we
significantly extend our model to allow for a target cell
population with a heterogeneous surface epitope density.
This allows us to analyze experiments where the percent-
age of target cells bound is determined as a function of
the ligand concentration. We also extend the model to
address the possibility that some fraction of the target
epitopes are immobile, including cases in which the im-
mobile fraction depends on epitope cross-linking or the
size of the contact region. These cases model some po-
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2tential target cell responses to adhesion.
To test predictions of the model we use an experi-
mental system consisting of a planar bilayer containing
mobile FcγRIIIb (CD16b) receptors, Jurkat T cells ex-
pressing the cell-adhesion molecule CD2, and a drug,
alefacept, that binds the target cell to the bilayer [12].
FcγRIIIb differs from FcγRIIIa, the receptor on NK
cells, in that it lacks a transmembrane region and a cyto-
plasmic tail and anchors to membranes via glycosolphos-
phatidylinositol [13]. Further, the extracellular domains
of the two receptors differ by six amino acids, which
probably accounts for FcγRIIIb having a lower affinity
for IgG than FcγRIIIa [13, 14]. Alefacept is a recombi-
nant fusion protein that has an antibody-like architec-
ture where the Fab binding sites have been replaced by
the natural ligand for CD2, the extracellular domain of
CD58 [15, 16], fused to the human IgG1 hinge, CH2, and
CH3 domains [2]. It is used in the treatment of psoriasis,
an autoimmune disease, where it targets memory-effector
T cells that have increased levels of CD2 on their surface.
Alefacept reduces the number of circulating memory-
effector T cells in treated patients and mediates ADCC
in vitro [2, 17–20].
Alefacept is an example of an immunoadhesin, which
is molecule that uses the basic framework of an IgG
antibody, but replaces the Fab binding sites with the
ecotodomain of an adhesion molecule. Immunoadhesins
have the specificity of an adhesion molecule as well as
some properties of an antibody, such as the ability to
bind to Fc receptors and a half-life in plasma that is sim-
ilar to IgG [21, 22]. An interesting property of alefacept
is that it mediates adhesion and killing of target cells by
NK cells at nM concentrations [12] even though both the
binding of IgG to FcγRIIIa and the binding of CD58 to
CD2 [23] are low affinity, in the µM range. The model we
present will show how the range of drug concentrations
over which adhesion occurs depends on these equilibrium
constants as well as the other parameters of the system.
II. MODEL AND METHODS
We consider a population of target cells expressing a
particular epitope, with some fraction of the epitopes
freely diffusing in the target cell membrane and the re-
mainder immobile, i.e. fixed in position on the mem-
brane. Additionally, we consider a bilayer with mobile
receptors diffusing on its surface and a ligand capable of
simultaneously binding both the epitope and the recep-
tor through different sites. The ligand is either a mono-
clonal antibody or an immunoadhesin; its Fab arms bind
monovalently or divalently to the epitope on the target
cells, and its Fc leg binds monovalently to the receptor
on the bilayer. At some ligand concentration a contact
region forms between the cell and the bilayer; its area is
an increasing function of the number of ligand-mediated
bridging bonds that form.
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FIG. 1: Model reaction network. All molecular species and
reactions are labeled. All reactions are reversible; the arrow
in the figure denotes the forward direction for defining the
equilibrium constant, which labels the arrow. Underlined rate
constants are eliminated using detailed balance.
A. Concentrations and equilibrium constants
The potential reactions between epitopes, ligand, and
receptor are illustrated in Fig. 1. Each molecular com-
plex is labeled by our mathematical notation for its sur-
face concentration. All species except those involving a
bridging bond (b10, b20, b11, and b01) exist both inside
and outside the contact region, and the subscript ‘in’
denotes species inside the contact region. Detailed bal-
ance places six constraints on the equilibrium constants,
which we use to eliminate the underlined constants in
Fig. 1 (see Supporting Material for more detail.) To find
the equilibrium state of this system for any given bulk
ligand concentration L, we solve five algebraic equations
for five unknowns: the free immobile epitope concentra-
tion outside i and inside iin the contact region, the free
mobile epitope e and receptor r concentrations outside
the contact region, and the fraction of the target cell
surface δ comprising the contact region. To make anal-
ysis tractable, we make several simplifying assumptions
regarding the equilibrium configuration of receptors and
epitopes.
Our first assumption is that the equilibrium constants
for reactions involving immobile epitopes are identical to
the corresponding constants involving mobile epitopes:
KI = KE , KHE = Kx, Kb01 = Kb10 ≡ Kb1, and
KFH = Kb20 ≡ Kb2. Making this assumption substan-
3tially reduces the number of unknown parameters. We
expect that this assumption leads to negligible error, be-
cause the relevant physical interactions are identical for
mobile and immobile epitopes.
Our second assumption is that the typical distance be-
tween immobile epitopes on the target cell is large com-
pared with the span of the two arms of the ligand, so that
the ligand cannot cross-link immobile epitopes. Thus we
do not consider complexes containing more than one im-
mobile receptor. Given a CD2 surface density ρ, and as-
suming the CD2 epitopes are uniformly distributed, the
probability P (d < a) that an epitope’s nearest neighbor
is a distance a away or closer is [24]:
P (d < a) = 1− e−piρa2 . (1)
As detailed later, each T-cell contains of order 64,000
CD2 epitopes, over a surface area of roughly 800 µm2,
yielding a density of ρ = 80µm−2. Given this den-
sity, the probability that an epitope’s nearest neighbor
is closer than the span of roughly 10 nm [25] between
epitope binding arms of an antibody-like molecule, such
as alefacept, is less than 3%. We expect that cross-links
between immobile epitopes will indeed be rare because
the density of immobile epitopes is even lower than the
total epitope surface density.
Our third assumption relates the free mobile epitope
and receptor concentrations inside and outside the con-
tact region. In earlier experiments, fluorescently labeled
CD48 (Cy5-CD48) was coupled to the bilayer, and it was
observed that the fluorescence from CD48 was reduced
in the contact region to approximately 75% of its value
outside the contact region [12]. This suggests that the
contact region introduces steric hindrance and partitions
mobile surface proteins between the inside and outside
of the contact region. We assume that at equilibrium
ein = σEe and rin = σRr, where ein and rin are the
free epitope and free receptor concentrations inside the
contact region and σE and σR are equilibrium partition
coefficients. The partition coefficients for FcγRIIIb and
CD2 have not been determined; we assume they behave
similarly to CD48 because they are of similar size, so we
take σR = σE = 0.75.
Using the law of mass action and these additional as-
sumptions, we can write down the equilibrium concentra-
tion of all bound complexes in terms of the free epitope,
receptor, and ligand concentrations. For example, the
concentration hin of complexes inside the contact region
consisting of a ligand cross-linking a mobile and an im-
mobile epitope is:
hin = Kxiine1in = 2KxKELiinein = 2KxKELσEiine.
(2)
The factor of 2 in calculating the concentration e1in of
complexes between a ligand and mobile epitope arises be-
cause KE is a single-site equilibrium constant, and there
are two potential binding sites on the ligand. Similarly,
the concentration b11 of bridging complexes involving a
TABLE I: Fixed parameter values
parameter value reference
KR 1.0× 106 M−1 [27–29]
KE 6.7× 105 M−1 [16]
Kx 4.5× 10−2 µm2 this work
σE 0.75 [12]
σR 0.75 [12]
Acell 800 µm
2 [12]
Aoff 6.2 µm
2 this work
receptor, a mobile epitope, and an immobile epitope is:
b11 = Kb2hinrin = Kb2hinσRr. (3)
The full system of equilibrium relations is given in Sup-
porting Material.
Given our assumptions, in the limit that target cells
are sparse the equilibrium state will depend on five equi-
librium constants (KR, KE , Kx, Kb1, and Kb2), two par-
tition coefficients (σE and σR), the total receptor rT , epi-
tope eT , and ligand concentrations LT , the epitope im-
mobile fraction η, and a parameter β that relates the area
of the contact region to the number of bridging bonds. In
addition, to connect our model with the data, we require
the surface area Acell of the Jurkat T cells studied, and
an offset area Aoff that accounts for non-specific adhesion
between the cells and the bilayer (detailed later). In our
analyses, a number of these parameters were held fixed
(Table I).
Most of our fixed parameter values come directly from
measurements; an exception is Kx, the cross-linking con-
stant for alefacept binding. To estimate Kx, we equate
the measured apparent dissociation constant KD for ale-
facept adhering to T cells to the inverse of the initial slope
m0 of a Scatchard plot for a bivalent ligand binding to a
monovalent receptor [26]:
m0 = −2KE(1 +KxeT )
2
1 +KxeT /2
= − 1
KD
. (4)
Using the mean CD2 count measured for our cells of
6.4 × 104 and Acell to calculate eT , along with KD =
100 nM [12] yields the value for Kx in Table I. With the
exception of the fit parameter Kb2, our results are insen-
sitive to the precise value of Kx (Fig. S.1 in Supporting
Material). The parameter Aoff is inferred from our data,
as discussed below.
B. Conservation laws
In the experiments we consider, there is negligible de-
pletion of ligand so the free ligand concentration is well
approximated by the total ligand concentration (L ≈
LT ). Conservation of epitopes and receptors, however,
introduces additional constraints on the concentration of
various complexes.
4In our model, there are three classes of epitopes: mo-
bile epitopes, immobile epitopes outside the contact re-
gion, and immobile epitopes inside the contact region.
We assume that the concentrations of all species have
reached equilibrium. For mobile epitopes, we have
Acell(1− η)eT = (Acell −A)(e+ e1 + 2e2 + h)
+A(b10 + 2b20 + b11 + ein + e1in + 2e2in + hin), (5)
where eT is the average epitope density on the cell sur-
face, equal to the total epitope count ET divided by the
cell area Acell, and A is the area of the contact region.
This equation expresses the fact that the total number
of mobile epitopes (left-hand side) must be equal to the
total number in complexes outside and inside the contact
region. In terms of the fraction δ of the cell surface in
the contact region, the above conservation law is:
(1− η)eT = (1− δ)(e+ e1 + 2e2 + h)
+ δ(b10 + 2b20 + b11 + ein + e1in + 2e2in + hin). (6)
Similarly, for immobile epitopes outside the contact re-
gion we have
η eT = i+ i1 + h, (7)
and for immobile epitopes inside the contact region we
have
η eT = iin + i1in + hin + b01 + b11. (8)
For receptors in the bilayer, we have
Abl rT = A(rin + r1in + b10 + b20 + b01 + b11)
+ (Abl −A)(r + r1), (9)
where Abl is the total area of the bilayer divided by the
number of adhered cells. Dividing by Acell and rearrang-
ing yields
rT = αδ(rin + r1in + b10 + b20 + b01 + b11)
+ (1− αδ)(r + r1), (10)
where α = Acell/Abl. In the experiments we analyze, for
all ligand concentrations the adhered cells are sparsely
distributed over the bilayer, so we take α = 0.
C. Contact region growth law
Bell, Dembo, and Bongrand argued [30] that the bridg-
ing bond density between two adhered cells is determined
by a constant repulsive pressure arising from electrostatic
repulsion caused by negative charges associated with cell
surfaces and steric stabilization effects. The steric ef-
fects arise because cell membranes are coated by a hy-
drated layer of long-chain polymers (glycocalyces) that
must compress as cells are brought together and water
is squeezed out of the contact region. Together with the
assumption that cells are easily deformed, this argument
implies that the area of the contact region grows linearly
with the number of bridging bonds.
Although we expect the repulsion between our tar-
get cells and bilayer to be smaller than that between
two cells, we expect the repulsive forces to be of similar
origin. Moreover, in our experiments the small contact
regions observed cause only small cellular deformations,
and our target Jurkat T cells are significantly more easily
deformed than some other cell types, such as neutrophils
and HL60 cells [31]. However, in our equilibrium data,
the observed average area of the contact region 〈Aobs〉
does not go to zero as the number of bridging bonds goes
to zero (Fig. 3A), an effect seen previously in the bind-
ing of Jurkat T cells to bilayers containing the natural
CD2 ligand CD58 [32]. We hypothesize that some addi-
tional non-specific adhesion occurs after cells settle onto
the membrane. We account for this effect by subtracting
an offset area Aoff from our data, so that in our modeling
we compare with the average specific adhered area 〈A〉,
which is 〈Aobs〉−Aoff . Our procedure for estimating Aoff
is discussed in the Results section. Once we have sub-
tracted the offset, we observe a linear relationship be-
tween average contact area and average bridging bond
number, suggesting that the bond density β is indeed a
constant. In addition to the constraints from conserva-
tion of epitopes and receptors, we thus have an additional
constraint on bond density:
β = b10 + b20 + b01 + b11. (11)
Solving the five constraint equations (Eq. 6, 7, 8, 10,
and 11) for the five unknowns e, i, iin, r, and δ allows us
to calculate the area of the contact region for a cell with
a specified epitope density eT given the ligand concentra-
tion L. We solve the constraint equations and perform all
numerics using the Python library SciPy [33]. Uncertain-
ties on fit parameters are calculated via bootstrapping,
with over 250 bootstrap data sets for each model.
D. Heterogeneous density of epitopes on target
cells
We now consider a target cell population with a nor-
malized distribution f(eT ) of epitope densities. For a
given ligand concentration, if eTmin is the minimum epi-
tope density at which adhesion will occur, the fraction of
cells bound to the bilayer is
fraction bound =
∫ ∞
eTmin
f(eT ) deT , (12)
and the average area of the specific contact region is
〈A〉 = Acell 〈δ〉 =
∫∞
eTmin
δ(eT )f(eT ) deT∫∞
eTmin
f(eT ) deT
. (13)
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FIG. 2: Distribution of CD2 epitope count on Jurkat T cells
like those used in our experiments, as determined by flow
cytometry.
We will primarily model the distribution of target cell
epitope densities by the three parameter Weibull distri-
bution, which has density
f(x; γ, k, λ) =
 kλ
(
x−γ
λ
)k−1
e−(
x−γ
λ )
k
if x > γ
0 if x ≤ γ.
(14)
In our fits, we fix the location parameter γ to zero. The
parameter k is the Weibull shape parameter. For k <
2.6, f(x) is skewed to the right, for 2.6 < k < 3.7 it is
essentially unskewed and looks like a normal distribution,
and for k > 3.7 it is skewed to the left. For k = 1 and
γ = 0 the Weibull distribution reduces to the exponential
distribution.
Shown in Fig. 2 is the distribution of expression of CD2
on the surfaces of a population of Jurkat T cells, the tar-
get cells in our study, as determined by flow cytometry.
This distribution serves as a baseline to judge the distri-
butions arising from our model fits. These measurements
were performed on a Becton Dickinson FacsCaliber. Flu-
orescein isothiocyanate (FITC) labeling of antibodies and
the determination of the fluoresceine:protein ratio was
determined using absorption spectroscopy [34]. Calibra-
tion was performed using FITC standard beads obtained
from Bangs Laboratories (Fishers, IN). Antibody-stained
cells were washed twice prior to analysis.
E. Analysis of the model with fully mobile epitopes
When all epitopes are mobile (η = 0) and there is no
depletion of bilayer receptors (α = 0) the model simpli-
fies substantially to a system of three equations for e, r,
and δ. This reduced system offers several useful analytic
results.
1. Requirements for adhesion
For a fixed epitope density, adhesion occurs over a
range of soluble ligand concentrations: L− ≤ L ≤ L+.
Similarly, for a fixed ligand concentration, adhesion oc-
curs only above a minimal epitope density eTmin. As L or
eT approach these bounds, the contact area approaches
some minimal value Amin below which there is no adhe-
sion. We make the approximation that Amin = 0. Plug-
ging δ = 0 into Eq. 6, 10, and 11 and substituting our
expressions for equilibrium species concentrations (such
as Eq. 2) yields a system of three equations for the un-
knowns e, r, and L. For a fixed epitope density eT , this
system can be reduced to a single cubic equation in L,
which is given in Supporting Material. This cubic equa-
tion may have either two positive roots (L− and L+) or
no positive roots (no adhesion irrespective of L). Sim-
ilarly, for a fixed ligand concentration L, the system of
three equations can be reduced to a quadratic equation
for eT , the larger root of which is eTmin (see Supporting
Material).
We expect that taking δ = 0 rather than setting it
equal to some minimal value introduces negligible error in
our estimates of L−, L+, and eTmin. In our experiments
adhesion was determined in the absence of flow, based
on whether there was accumulation of the receptor CD58
in the contact area. Even in the presence of weak flows,
estimates suggest that few bonds, and thus small contact
areas, are needed to maintain adhesion [35, 36].
2. Average contact area
When the cells adhered to the bilayer negligibly deplete
the receptors so that α = 0, and all epitopes are mobile
so that η = 0, then
〈δ〉 = δ(〈eT 〉) (15)
where 〈eT 〉 is the average epitope density of adhered cells:
〈eT 〉 =
∫∞
eTmin
eT f(eT ) deT∫∞
eTmin
f(eT ) deT
. (16)
To prove this, we first note the constraint imposed by our
relation for the bond density (Eq. 11) when α = 0 and
η = 0. In this case, after substituting our equilibrium
relations, β is equal to a function of e and r which does
not involve eT . When α = 0, r is simply rT /(1 + KRL)
(from Eq. 10), again not involving eT . Thus, our relation
for the bond density provides a constraint on the free
epitope density e that is independent of the total epitope
density eT . In other words, all adhered cells will have
the same density of free epitopes and thus of all other
complexes, irrespective of their total epitope density eT .
When α = 0 and η = 0, our conservation equation for
mobile epitopes (Eq. 6) yields the following expression
for δ:
δ =
eT − (e+ e1 + 2e2)
b10 + 2b20 + ein + e1in + 2e2in − (e+ e1 + 2e2)
(17)
6Note that all complex concentrations on the right-hand-
side (e, e1, e2, b10, b20, ein, e1in, and e2in) are functions of
e and r only, which we have just shown are independent
of eT . Thus, taking the average over adhered cells, we
have
〈δ〉 = 〈eT 〉 − (e+ e1 + 2e2)
b10 + 2b20 + ein + e1in + 2e2in − (e+ e1 + 2e2) ,
(18)
where the right-hand-side is simply the specific contact
area calculated using the average epitope density of ad-
hered cells, 〈eT 〉. Thus, for the case in which α = 0 and
all receptors are mobile, calculating 〈δ〉 does not require
explicitly integrating δ(eT ) over our epitope density dis-
tribution f(eT ). Instead we need only calculate eTmin,
then 〈eT 〉, and finally 〈δ〉.
F. Calculations with immobile fraction
Analysis of the model with non-zero immobile epitope
fraction (η > 0) is considerably more difficult than the
case of completely mobile epitopes, even with α = 0. To
calculate δ we must now numerically solve a system of
five, rather than three, algebraic equations. Addition-
ally, the simplifications of the previous section no longer
apply, so we must find the bounding ligand and epitope
concentrations for adhesion using numerical root-finding,
and we must calculate 〈δ〉 by explicit numerical integra-
tion of δ(eT ) over the distribution f(eT ).
When η > 0, direct solution of our system of five
constraint equations will give non-physical results for
those cases in which the immobile epitopes themselves
are dense enough to drive adhesion. Because the im-
mobile epitope density is assumed constant over the cell
surface, this case results in a divergent contact area δ, as
demonstrated in Fig. S.2. In our application, this phe-
nomenon only occurs at very high total epitope densities
eT , so it makes only a small contribution in our typical in-
tegrations over f(eT ), but we must handle it carefully to
avoid numerical difficulties. The value of η which leads to
this divergence, ηdiv can be found by solving our conser-
vation equation for immobile epitopes inside the contact
region (Eq. 8) with b01 = β, yielding
ηdiv = β
1 + 2KIL(1 +Kb1rin)
2Kb1KILeT rin
. (19)
When η > ηdiv, we set δ = 0.5, consistent with a cell
completely flattened against the surface. Similarly, we
set δ = 0.5 whenever direct solution of the equations
would yield a larger value for δ. Altering this maximum
value of δ has very small influence on our results (data
not shown), as in our experiments the vast majority of
cells have only a small fraction of their area adhered.
In our analyses, we consider fits with a constant im-
mobile fraction, and fits in which the immobile fraction
η is a function of either δ or the fraction κ of target cell
epitopes that are cross-linked by ligand:
κ =
2δ(e2in + b20 + hin + b11) + 2(1− δ)(e2 + h)
eT
. (20)
In both cases we consider a linear dependence of η on δ
or κ:
η = 0.13 + sδδ, (21)
or
η = 0.13 + sκκ. (22)
Here 0.13 is the experimentally observed immobile epi-
tope fraction in the absence of ligand [12]. Eq. 21 or 22
represents an additional constraint to our previous five,
to account for the additional free variable η. There may
be multiple self-consistent solutions of our expanded sys-
tem of six constraint equations (see Fig. S.2). Physically,
we expect the cell to adopt the solution corresponding
to smaller η, as the cell begins in a state with minimal
epitope immobility. In our calculations we always adopt
the smallest possible solution.
III. RESULTS
Experiments were previously carried out to character-
ize alefacept-mediated bridging of CD2 epitopes on Ju-
rkat T-cells to fluorescently-labeled FcγRIIIb receptors
on supported bilayers [12]. The alefacept concentration L
was varied from 1 nM to 100 µM and the fraction of cells
bound to the bilayer, the average size of the contact area,
and the average number of bonds in the contact area were
determined. These types of measurements were made at
two different FcγRIIIb densities rT on the bilayer: 1200
µm−2 and 625 µm−2. Here we fit several models of in-
creasing complexity to this data. Using these models, we
then consider the requirements for alefacept-mediated T-
cell adhesion, deriving compact expressions for the lim-
iting alefacept concentrations. Finally, we consider the
effect of background nonspecific IgG on adhesion.
In Fig. 3A the bridging bond data is plotted against
the area of the contact region. From this data we extract
a best-fit value for the non-specific contact area of Aoff =
6.17µm2, with a 95% confidence interval of 2.8–8.5 µm2.
In all our subsequent fits, this value is subtracted from
the contact area data, so we only fit the specific contact
area.
A. Fit of fully mobile model
We first considered an adhesion model with free diffu-
sion of all FcγRIIIb receptors on the bilayer and all CD2
epitopes on the T cell. Simultaneous nonlinear least-
squares fits of this model to the data are shown by the
solid lines in Fig. 3B. We weighted the experiments so
7TABLE II: Fit results (best-fits and 95% confidence intervals)
model χ2 β (µm−2) Kb1 (µm2) Kb2 (µm2) η sκ sδ k λ (×103) 〈ET 〉 (×103)
η = 0 1.658 413 1.3 54 1.9 6.2 5.5
364–487 0.3–3.0 23–108 1.7–2.3 5.1–8.3 4.5–7.3
η = constant 1.658 413 1.3 55 0 1.9 6.3 5.5
368–495 0.4–2.6 26–102 0–0.01 1.7–2.2 5.2–9.0 4.6–8.0
η = 0.13 + sκκ 1.663 414 1.3 55 0 1.9 7.2 6.4
362–483 0.4–2.6 25–94 0–0.06 1.7 – 2.2 5.9–9.7 5.3–8.6
η = 0.13 + sδδ 1.432 411 0.7 5.5 42 1.5 21 19
361–487 0.3–1.6 2.2–17.4 26–56 1.2–1.8 11–36 10–32
B
A
FIG. 3: A: Experimental data on average bridging bond count
versus average contact area. Once the non-specific adhesion
offset Aoff is removed, a linear relationship is evident. We
plot the model with β = 410/µm2 (line). B: Fits to contact
area, bridging bond, and fraction-adhered data for the best-
fit model with all T-cell epitopes mobile (solid lines) and the
best-fit model with epitope immobility η a linear function of
the contact area δ (dashed lines).
that both the bond and contact area data went between
zero and one, and we fit five parameters: the bridging
bond density β, the equilibrium constants Kb1 and Kb2,
and the Weibull distribution parameters k and λ. Ta-
ble II lists the best-fit values of the free parameters, along
with 95% confidence intervals. The best-fit value for the
average number of epitopes per cell was roughly 5,500,
which is much smaller than the average value of 64,000
determined from flow cytometry (Fig. 2). A reasonable
fit could not be obtained when the distribution of epi-
topes per cell was taken directly from the flow cytometry
data (data not shown).
One counter-intuitive property of the fits is that at high
and low ligand concentrations it appears as if there is a
slow decline in the average contact area and number of
bridging bonds long after the number of bound cells has
gone to zero. In these cases, the average contact area
is being calculated over the miniscule fraction of cells
that are adhered. For example, with rT = 1200µm
−2, at
L = 10−4 µM an average of 125 bonds per adhered cell is
predicted, but this involves only a fraction 10−27 of the
total cells. In the experiments, only a few hundred cells
were sampled per data point, so the tails of the Weibull
distribution are a poor description of the cell population.
Whether the Weibull distribution is a reasonable descrip-
tion of the epitope density on a target cell population in
vivo is an open question. We have also considered a log-
normal distribution. Although it can fit the flow cytome-
try data in Fig. 2 well, when it is used to analyze the data
in Fig. 3, it predicts that as the ligand concentration de-
creases, the average contact area and number of bridging
bonds go through minima and then rise, yielding a very
poor fit to this data (results not shown). Thus, for the
lognormal distribution (and possibly other distributions)
the average number of bonds in the contact region can
increase as the ligand concentration goes to zero.
This model with freely diffusing CD2 epitopes dramat-
ically underestimates the amount of CD2 present on the
T cells. Therefore we consider more complex models in-
corporating immobile CD2 epitopes in the following sec-
tions.
B. Fit of models with epitope immobility
In prior experiments on Jurkat T cells, it was observed
that 13% of CD2 epitopes were immobile in the absence
of ligand [12]. It has further been observed in T cells
that cell stimulation may increase CD2 immobility [37].
Thus we extended our mathematical model to include
8potential CD2 epitope immobility and fit several such
models to the data.
We first considered a model in which the immobile epi-
tope fraction η was a fit constant. In this case, the best-fit
value of η was found to be zero, yielding an identical fit
to the fully mobile case. This motivated us to consider
models in which the immobile fraction was a function of
the fraction κ of epitopes cross-linked by ligand or the
fractional area δ of the specific contact region.
When we fit a model in which the immobile fraction
was a linear function of κ (restricting our search to slopes
≥ 0), the best-fit value for the slope of that function was
0, yielding a constant immobile fraction of 0.13. The
resulting model fit was slightly worse than the completely
mobile model.
The dashed curves in Fig. 3B show the results from
a fit with the immobile fraction a linear function of the
specific contact area δ. In this case, the fit is somewhat
improved, and the best-fit estimate of total epitope count
per cell is driven upward to roughly 19, 000. This esti-
mate of ET is still only a about a third of the value
inferred from the flow cytometry data, but it is much
closer than the other models. The best-fit function for
η is η = 0.13 + 43δ, so the immobile fraction increases
very rapidly with cell adhesion. Note that in our data,
the largest average specific contact area seen is roughly
12µm2/Acell = 0.015 so that only small values of δ are
typically explored, and adding higher-order terms to η(δ)
yields negligible improvement in the fit (data not shown).
C. Requirements for adhesion
For drug design, an important consideration is what
combinations of ligand concentration and target cell epi-
tope count will yield binding. The curves in Fig. 4A sepa-
rate the region where more than 50% of cells are adhered
(inside each curve) from the region where less than 50%
are adhered for three different scenarios. The outermost
thick solid curve is the predicted separation curve for the
parameters obtained from the fit with all receptors mo-
bile (that shown by the solid lines in Fig. 3B). From this
curve we can see that the minimal ligand concentration
for adhesion L− is inversely proportional to the square of
the epitope density, i.e. the bottom portion of the curve
has a slope of approximately negative two.
From the complete set of equations for the model with
η = 0 and α = 0, we can obtain simple approximations
for L− and L+ for a fixed target cell epitope density eT :
L− ≈ β
e2TKEKb2KxrTσ
2
EσR
(23)
and
L+ ≈ eTKb1rTσEσR
βKR
. (24)
To approximate L−, we assume that, at the lowest ligand
concentrations that mediate adhesion, all bridging bonds
arise from epitopes bound bivalently (so Kb1 = 0). For
the L+ approximation, we assume that, at the highest
ligand concentrations that mediate adhesion, all ligands
bound to epitopes are bound singly (so Kx = Kb2 = 0).
As seen in Fig. 4A, Eq. 23 and 24 closely predict the
ligand concentration of 50% adhesion, when we replace
eT by the average epitope density. Our approximate ex-
pression for L− suggests that ligands similar to alefacept
can achieve considerable selectivity in epitope density
on adhered cells, because L− falls with the square of
the epitope density. Further, since the ligand-epitope
cross-linking constant (Kx) is proportional to the ligand-
epitope binding constant (KE), Eq. 23 implies that L−
falls inversely with the square of KE , suggesting that a
good strategy for lowering L− is to develop ligands with
higher KE values.
The dashed curve in Fig. 4A bounds the region of ad-
hesion for the best-fit model in which the immobile frac-
tion η is a linear function of the contact area δ. Again,
the minimal ligand concentration for adhesion falls as the
square of the epitope density. Our expressions for L− and
L+ (Eq. 23 and 24) are no longer good approximations in
this case, but the dependence of L− on the ligand-epitope
binding constants KE and Kx is the same. This is illus-
trated by the dotted curve, which bounds the region of
adhesion for the same model and parameters, with the
exception that KE and Kx have been divided by 10. As
expected from Eq. 23, the minimal ligand concentration
for adhesion has increased by a factor of 100.
D. Adhesion inhibition by non-specific IgG
In vivo, alefacept-mediated adhesion depends not only
on the concentration of alefacept and the density of CD2
on the T cells, but also on the presence of background
nonspecific IgG, which can bind the NK cell receptor and
inhibit adhesion. To test the sensitivity of adhesion to
background concentrations of nonspecific IgG, the per-
centage of cells bound to the bilayer was determined in
the presence of 500 nM of the ligand (alefacept) and dif-
fering concentrations G of purified human IgG, with a re-
ceptor concentration in the bilayer of 450 µm−2 [12]. For
inhibition to be significant, we expect that KGG must
be greater than 1, where in these experiments the IgG
binding constant KG is equal to our KR. In Fig. 4B, an
inhibition of 50% is achieved with an IgG concentration
of about 7 µM, suggesting that KR ≥ 1.5×105 M−1. (In
our fits we took KR = 1.0 × 106 M−1 [27–29].) Fig. 4B
shows good agreement between our predicted inhibition
curve using the best-fit parameters for the η(δ) model
and the experimental data, providing further validation
of our model.
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FIG. 4: A: Curves shown enclose the region of greater than
50% cell adhesion, for the best-fit all-mobile model (thick
solid), the best fit model with η(δ) (dashed), and the η(δ)
model with ligand-epitope binding constants KE and Kx each
divided by 10 (dotted). The thin solid lines show our approx-
imations for the bounding ligand concentrations L− and L+.
B: Experimental data on the inhibition of adhesion by non-
specific IgG (open circles), compared with predictions from
our model with the immobile epitope fraction a function of
the contact area. The black line is from the best-fit model,
while the dashed lines denote 95% confidence intervals from
our bootstrap parameter uncertainties.
IV. DISCUSSION
We have developed an equilibrium model for the
ligand-mediated adhesion of cells to surfaces. Our model
incorporates potential heterogeneities in target cell epi-
tope density, immobility of epitopes, and the possibility
that ligand binding or adhesion alters the immobile epi-
tope fraction. We have applied our model to experiments
on the alefacept-mediated adhesion of Jurkat T cells ex-
pressing CD2 to bilayer membranes containing the recep-
tor FcγRIIIb, a close relative of the relevant receptor on
natural killer cells. We find that our data are best de-
scribed by a model in which the immobile epitope fraction
is a function of the contact area between the target cell
and bilayer. Nevertheless, our best-fit model still under-
estimates the epitope density on Jurkat T cells, perhaps
indicating that other factors influence CD2-mediated ad-
hesion and opening a direction for future study.
Our results also suggest general guidelines for the de-
sign of immuno-adhesive molecules. We find that, for
bivalent ligands, the minimal ligand concentration L−
required for adhesion is inversely related to the square
of the target cell epitope density, illustrating the poten-
tial selectivity of these ligands. We also show that L− is
a quadratic function of the epitope-ligand binding con-
stants, even for our more complex models, suggesting
that tuning this interaction may be a fruitful route for
drug design.
It is instructive to compare our fit parameters with
with those from previous investigations of Jurkat T cell
adhesion. A previous analysis of adhesion to bilayers con-
taining the natural CD2 binding partner, CD58, found
a non-specific contact area of 7.6 µm2, similar to the
6.17 µm2 we find [32]. That analysis found the density
of bridging bonds β at equilibrium to be approximately
1000 µm−2, substantially greater than our value of 400
µm−2. This is unsurprising, because the direct CD2-
CD58 interaction draws the cell closer to the bilayer,
leading to a larger repulsive force which requires more
bonds to overcome. Our value for the 2D association
constant Kb1 between the alefacept-epitope complex and
CD16b are of order 1 µm2. This value is similar to previ-
ous results for the 2D association constant between CD2
and CD58, which range from 0.1 to 0.9 µm2 [16, 37, 38].
Thus our fit parameters are consistent with those from
the literature.
Our data are best described by a model in which the
level of immobilized CD2 on the T cell is proportional to
the contact area, rather than the degree of CD2 cross-
linking. This suggests that signaling from isolated cross-
linked CD2 pairs may be less effective than signaling from
larger aggregates or from regions of high CD2 density,
such as the contact region. A similar effect is seen in
signaling from the immune receptor FcRI on rat ba-
sophilic leukemia cells, in which receptor dimers signal
weakly compared to larger aggregates [39]. Furthermore,
recent experiments have observed signaling in Jurkat T
cells adhering to bilayers presenting CD58, the natural
binding partner of CD2 [40].
In our system, comparing the bridging bond density β
of approximately 400 µm−2 with the initial cellular CD2
density of roughly 80 µm−2, we see that the density in-
crease in the contact region is roughly a factor of 5. This
increases the fraction of CD2 nearest neighbors within a
given distance by the same factor of 5 (Eq. 1), substan-
tially increasing the probability of interaction. Thus the
increased density of CD2 in the contact region may have
a large effect in promoting interactions between CD2
molecules and driving signaling. When alefacept adheres
T cells to NK cells in vivo, FcγRIIIa receptors on the NK
cell will be similarly concentrated in the contact region,
and this concentration may contribute to the signal that
drives NK-mediated killing of target cells. Moreover, we
expect the repulsive force to be greater between cells than
between a cell and a bilayer, so the in vivo bridging bond
density is probably larger, leading to greater in vivo re-
ceptor concentration than seen in our experiments.
In summary, we have developed an equilibrium model
for the immunoadhesin-mediated adhesion of cells to sur-
faces. Our analysis suggests guidelines for the design of
therapeutic immunoadhesins. Furthermore, applying our
model to experiments on Jurkat T cells suggests that an
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active cellular process may be increasing CD2 immobility
in response to alefacept-mediated surface adhesion.
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Supporting Material:
A biophysical model of cell adhesion mediated by immunoadhesin drugs and antibodies
S.1. Full model
The full set of equilibrium relations among the molecular complexes considered in our model is given by Eq. S.1
through S.16, which express all complex concentrations as functions of e, r, i, and iin:
ein = σEe, (S.1)
rin = σRr, (S.2)
e1 = 2KELe, (S.3)
e2 = Kxe1e/2, (S.4)
e1in = 2KELein, (S.5)
e2in = Kxe1inein/2, (S.6)
b10 = Kb10e1inrin, (S.7)
b20 = Kb20e2inrin, (S.8)
r1 = KRLr, (S.9)
r1in = KRLrin, (S.10)
i1 = 2KILi, (S.11)
i1in = 2KILiin, (S.12)
h = KHEe1i, (S.13)
hin = KHEe1iniin, (S.14)
b01 = Kb01i1inrin, and (S.15)
b11 = KFHhinrin. (S.16)
Note that the above equations do not involve any of the underscored equilibrium constants indicated in Fig. 1 of
the main text. This is because enforcing detailed balance around all loops in the reaction diagram introduces six
constraints on the equilibrium constants, which we use to eliminate the underlined constants:
KxKb20 = KxKb10, (S.17)
KEKb10 = KEKR, (S.18)
Kb10KFE = KFHKHE , (S.19)
KIKb01 = KIKR, (S.20)
KEKHE = KIKHI , and (S.21)
KIKb01KFI = KFHKHEKE . (S.22)
S.2. Requirements for adhesion
As described in the main text, for the model with all receptors mobile, we can find equations for the bounds on
ligand concentration L and epitope density eT for adhesion by setting δ = 0 in Eq. 6, 10, and 11.
In the model with all receptors mobile, to find the minimal epitope density eTmin for adhesion, we solve the quadratic
equation
ae e
2
T + be eT + ce = 0 (S.23)
where the coefficients are given by:
ae = K
′
b2
2
KEKxLr
2
T , (S.24)
be = 2KELrT
[
−4K ′b12KELrT +K ′b1K ′b2rT (1 + 2KEL)− 2K ′b2Kxβ(1 +KRL+KGG)
]
, and (S.25)
ce = β(1 +KRL+KGG)
{
4KEL [K
′
b1(rT + 2KELrT ) + βKx(1 +KRL+KGG)]−K ′b2rT (1 + 2KEL)2
}
, (S.26)
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with K ′b1 ≡ σRσEKb1 and K ′b2 ≡ σRσ2EKb2. Eq. S.23 has two solutions, the larger of which is eTmin.
To find the limits on ligand concentration for adhesion, we solve the cubic equation
aL L
3 + bL L
2 + cL L+ dL = 0 (S.27)
where the coefficients are given by:
aL = 4βKEKR(2rTK
′
b1KE − rTK ′b2KE + βKRKx), (S.28)
bL = −4KE
{
βrT [K
′
b2(KE +KR)−K ′b1rT (2KE +KR)− 2KRKxβ] (S.29)
+ eT rT (2K
′
b1
2
KErT −K ′b1K ′b2KErT +K ′b2KRKxβ)
}
,
cL = 2rTK
′
b1KE(2β + eT rTK
′
b2) + 4β
2KEKx + e
2
T r
2
TK
′
b2
2
KEKx − rTβK ′b2 [KR + 4KE(1 +KxeT )] , and (S.30)
dL = −rTβK ′b2. (S.31)
Eq. S.27 has either two positive solutions, which are L− and L+, or no positive solutions, in which case adhesion is
not possible for any ligand concentration.
S.3. Sensitivity to Kx
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FIG. S.1: Sensitivity to Kx. The change in best-fit parameter values for the completely mobile model is plotted as Kx varies
from our inferred value of 4.5 × 10−2 µm2. With the exception of Kb2, changing Kx by a factor of 10 up or down from this
value changes the best-fit results by less than 30%. The best-fit value of Kb2, on the other hand, is inversely proportional to
the value of Kx assumed.
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S.4. Model solutions and divergence
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FIG. S.2: Illustrative solutions of our model as a function of immobile fraction η. We show the solution for δ as a function of
η for a particular set of model parameters (open circles). Note divergence at ηdiv ≈ 0.95. We show the filtered solution for δ,
accounting for the divergence and fixing δ ≤ 0.5 (thick solid line), and the fraction κ of cross-linked epitopes as a function of η
(dashed line). We also show two potential models with η constrained to be a linear function of κ or δ (thin solid lines). The
solution for δ(η) with η = 0.13 + 2δ is shown by the star, while the solution for δ(η) with η = 0.13 + κ is shown by the large
diamond.
